What Is CAR T-Cell Therapy?
CAR T-cell therapy trains a type of your body’s white blood cells, called T-cells, to recognize and fight cancer. The cells are removed from your blood, altered in a lab, then returned to your body through an infusion.
Candidates for CAR T-Cell Therapy
Candidates for CAR T-cell therapy have failed two separate systemic treatments -- which could include chemotherapy or bone marrow or stem cell transplants -- and by a relapsed after each.
Types of non-Hodgkin lymphomas eligible for treatment with Yescarta and/or Kymriah include:
- Diffuse large B-cell lymphoma (DLBCL)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- High grade B-cell lymphoma
- DLBCL arising from follicular lymphoma (FL)
Additionally, Kymriah can also be used to treat patients up to the age of 25 who have some kinds of B-cell acute lymphoblastic leukemia (ALL).
As part of your evaluation to receive CAR T-cell therapy, you’ll consult with Duke specialists to see if it’s right for you. This evaluation includes a meeting with a financial counselor to determine how health insurance may cover this new therapy.
If you aren’t eligible for CAR T-cell therapy, there may be other options for treatment, and we can work with you to see if there are clinical trials offered at Duke to treat your disease in another way.